Quoin Pharmaceuticals
Open
$6.35
Prev. Close
$6.35
High
$6.45
Low
$6.35
Market Snapshot
$8.71M
-0.6
4
Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
emptyResult
Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
Recently from Cashu
Quoin Pharmaceuticals at GenScript Biotech's Forum: Driving Innovation in Biotechnology
GenScript Biotech's Annual Forum: A Catalyst for Innovation in Biotechnology GenScript Biotech Corporation is set to host its 5th Annual Biotech Global Forum on January 14, 2026, at the San Francisco…
Quoin Pharmaceuticals Welcomes Dr. Glickman to Board for Genome Editing Growth Initiatives
Specific Biologics Appoints Dr. Richard Glickman to Board, Aiming at Growth in Genome Editing Specific Biologics Inc., a precision in vivo genome editing company, enhances its leadership with the appo…
Quoin Pharmaceuticals Progresses Rare Disease Treatments with QRX003 for Netherton Syndrome
Quoin Pharmaceuticals Advances in Rare Disease Therapeutics Quoin Pharmaceuticals is making significant strides in the development of therapeutics for rare diseases, particularly focusing on the treat…
Quoin Pharmaceuticals Makes Progress in Rare Disease Treatments with QRX003 Development
Quoin Pharmaceuticals Advances in Rare Disease Treatments Quoin Pharmaceuticals, a biopharmaceutical company focused on developing innovative therapies for rare diseases, announces significant progres…